Akari Therapeutics (AKTX) Net Income (2014 - 2026)

Akari Therapeutics has disclosed Net Income across 9 years of filings, most recently posting -$14.5 million for Q1 2026.

• Net Income for Q1 2026 came in at -$14.5 million, down 290.15% year-over-year; the trailing twelve-month figure through Mar 2026 was -$29.3 million (down 64.09% YoY), and the FY2025 annual result was -$17.3 million, up 12.6% from the prior year.
• Net Income came in at -$14.5 million for Q1 2026 at Akari Therapeutics, down from -$5.3 million in the prior quarter.
• In the past five years, Net Income ranged from a high of -$2.5 million in Q3 2023 to a low of -$14.5 million in Q1 2026.
• The 4-year median for Net Income is -$4.6 million (2023), against an average of -$5.4 million.
• Across the five-year window, Net Income soared 57.74% in 2025 and plunged 290.15% in 2026, its largest moves.
• Akari Therapeutics' Net Income stood at -$5.1 million in 2023, then advanced by 25.79% to -$3.8 million in 2024, then slumped by 40.46% to -$5.3 million in 2025, then tumbled by 172.84% to -$14.5 million in 2026.
• The last three Net Income figures came in at -$14.5 million (Q1 2026), -$5.3 million (Q4 2025), and -$6.4 million (Q3 2025), per Business Quant data.